Because Arc is a potent inhibitor of AR signaling in LAPC-4 prostate cancer cells, the combined effects of Arc and quercetin on proliferation, apoptosis, cell migration, and underlying mechanisms in both androgen-dependent prostate cancer cell lines (LNCaP and LAPC-4) have been reviewed. Here, ARC is linked to prostate cancer.